📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Defining disease modification in myelofibrosis in the era of targeted therapy. (2022)

First Author: Pemmaraju N

Attributed to: The Oxford Single Cell Biology Consortium funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1002/cncr.34205

PubMed Identifier: 35499819

Publication URI: http://europepmc.org/abstract/MED/35499819

Type: Journal Article/Review

Volume: 128

Parent Publication: Cancer

Issue: 13

ISSN: 0008-543X